{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:14:19Z","timestamp":1759331659023,"version":"build-2065373602"},"reference-count":77,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.arcmed.2018.12.011","type":"journal-article","created":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T08:54:24Z","timestamp":1546246464000},"page":"558-567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Innovative Strategies in Heart Failure: Present and Future"],"prefix":"10.1016","volume":"49","author":[{"given":"Mois\u00e9s","family":"Rodr\u00edguez-Ma\u00f1ero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian","family":"Grigorian-Shamagian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregorio","family":"R\u00e1bago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charigan","family":"Abou-Jokh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belen","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Brion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Gonz\u00e1lez-Juanatey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2018.12.011_bib1","first-page":"e38","article-title":"American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart disease and stroke statistics-2016 update: a report from the American Heart Association","volume":"133","author":"Writing Group","year":"2016","journal-title":"Circulation"},{"year":"2002","series-title":"MS. Heart failure therapy: past, present, and future","author":"Anne Staylor","key":"10.1016\/j.arcmed.2018.12.011_bib2"},{"key":"10.1016\/j.arcmed.2018.12.011_bib3","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jchf.2014.09.001","article-title":"Combined neprilysin and reninangiotensin system inhibition for the treatment of heart failure","volume":"2","author":"Vardeny","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.arcmed.2018.12.011_bib4","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2018.12.011_bib5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.232","article-title":"Renal effects of the angiostensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction","volume":"17","author":"Voors","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.arcmed.2018.12.011_bib6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","article-title":"Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction. Rationale and Design of the PARAGON-HF Trial","volume":"5","author":"Solomon","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.arcmed.2018.12.011_bib7","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2018.12.011_bib8","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1161\/CIRCULATIONAHA.115.017594","article-title":"Intensive management to reduce hospitalizations in patients with heart failure","volume":"133","author":"Desai","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.arcmed.2018.12.011_bib9","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensinreceptor- neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arcmed.2018.12.011_bib10","first-page":"e282","volume":"134","author":"Yancy","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.arcmed.2018.12.011_bib11","first-page":"8","article-title":"Sacubitril\/Valsartan Initiated in Hospitalized Patients with Heart Failure with Reduced Ejection Fraction after Hemodynamic Stabilization: Primary Results of the TRANSITION Study","volume":"24","author":"Watcher","year":"2018","journal-title":"J Cardiac Fail"},{"key":"10.1016\/j.arcmed.2018.12.011_bib12","doi-asserted-by":"crossref","unstructured":"Watcher R, Senni M, Belohlavek J, et\u00a0al. Initiation of sacubril\/valsartan in hospitalized patients with heart failure with reduced ejection fraction after hemodynamic stabilization: Primary results of the TRANSITION study. Data presented at: European Society of Cardiology Munich, Germany 2018;S1: ehy564.P886.","DOI":"10.1093\/eurheartj\/ehy564.P886"},{"key":"10.1016\/j.arcmed.2018.12.011_bib13","article-title":"Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure","author":"Velazquez","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2018.12.011_bib14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1358\/dot.2017.53.10.2722396","article-title":"Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients","volume":"53","author":"Zaid Iskandar","year":"2017","journal-title":"Drugs Today"},{"key":"10.1016\/j.arcmed.2018.12.011_bib15","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2018.12.011_bib16","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2018.12.011_bib17","article-title":"On behalf of the DECLARE\u2013TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","author":"Wiviott","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2018.12.011_bib18","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.arcmed.2018.12.011_bib19","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/1440-1681.12725","article-title":"Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats","volume":"44","author":"Rahman","year":"2017","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.arcmed.2018.12.011_bib20","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/HJH.0000000000001434","article-title":"Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2","volume":"35","author":"Matthews","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.arcmed.2018.12.011_bib21","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcomes trials","volume":"9","author":"Zelniker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2018.12.011_bib22","unstructured":"Dr. Subodh Verma et\u00a0al. EMPA-HEART Cardiolink-6- EMPA-HEART. The American Heart Association Annual Scientific Sessions (AHA 2018). Data presented at: AHA 2018. November 11; Chicago."},{"key":"10.1016\/j.arcmed.2018.12.011_bib23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","article-title":"Impact of dapagliflozin on left ventricular diastolic function on patients with type 2 diabetic mellitus with chronic heart failure","volume":"17","author":"Soga","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.arcmed.2018.12.011_bib24","first-page":"52","article-title":"Expert\u015brecommendations for the management of adult patients with cardiogenic shock","volume":"5","author":"Levy","year":"2015","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.arcmed.2018.12.011_bib25","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.arcmed.2018.12.011_bib26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Steering Commiitee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2018.12.011_bib27","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.arcmed.2018.12.011_bib28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jchf.2012.12.004","article-title":"REVIVE Heart Failure Study Group. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure","volume":"1","author":"Packer","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.arcmed.2018.12.011_bib29","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1616325","article-title":"Levosimendan for hemodynamic support after cardiac surgery","volume":"376","author":"Landoni","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2018.12.011_bib30","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1616218","article-title":"Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery","volume":"376","author":"Mehta","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2018.12.011_bib31","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ejhf.1145","article-title":"LION-HEART Study Investigators. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial","volume":"20","author":"Comin-Colet","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.arcmed.2018.12.011_bib32","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2018.12.011_bib33","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/01.CIR.0000065226.24159.E9","article-title":"Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure","volume":"107","author":"St John Sutton","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.arcmed.2018.12.011_bib34","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0735-1097(98)00492-6","article-title":"Acute hemodynamic effects of biventricular DDD pacing in patients with end-stage heart failure","volume":"32","author":"Leclercq","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arcmed.2018.12.011_bib35","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.amjcard.2004.12.023","article-title":"Use of cardiac resynchronization therapy to optimize betablocker therapy in patients with heart failure and prolonged QRS duration","volume":"95","author":"Aranda","year":"2005","journal-title":"Am J Cardiol"},{"issue":"27","key":"10.1016\/j.arcmed.2018.12.011_bib36","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.arcmed.2018.12.011_bib37","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2009.08.045","article-title":"Optimizing hemodynamics in heart failure patients by systematic screening of left ventricular pacing sites: the lateral left ventricular wall and the coronary sinus are rarely the best sites","volume":"55","author":"Derval","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arcmed.2018.12.011_bib38","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.105.543678","article-title":"Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy","volume":"113","author":"Bleeker","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.arcmed.2018.12.011_bib39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ahj.2006.10.015","article-title":"Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy","volume":"153","author":"Adelstein","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.arcmed.2018.12.011_bib40","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1161\/CIRCULATIONAHA.109.894774","article-title":"Analysis of ventricular activation using surface electrocardiography to predict left ventricular reverse volumetric remodeling during cardiac resynchronization therapy","volume":"121","author":"Sweeney","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.arcmed.2018.12.011_bib41","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1161\/01.CIR.101.8.869","article-title":"Permanent, direct His-bundle pacing: a novel approach to cardiac pacing in patients with normal His-Purkinje activation","volume":"101","author":"Deshmukh","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.arcmed.2018.12.011_bib42","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jacc.2018.06.017","article-title":"His Bundle Pacing","volume":"72","author":"Vijayaraman","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arcmed.2018.12.011_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/europace\/eus228","article-title":"Ventricular resynchronization therapy by direct His-bundle pacing using an internal cardioverter defibrillator","volume":"15","author":"Barba-Pichardo","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.arcmed.2018.12.011_bib44","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.hrthm.2015.03.048","article-title":"His-bundle pacing versus biventricular pacing in cardiac resynchronization therapy patients: a crossover design comparison","volume":"12","author":"Lustgarten","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.arcmed.2018.12.011_bib45","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.hrthm.2017.04.003","article-title":"Permanent His-bundle pacing for cardiac resynchronization therapy: initial feasibility study in lieu of left ventricular lead","volume":"14","author":"Ajijola","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.arcmed.2018.12.011_bib46","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.hrthm.2017.10.014","article-title":"Permanent His bundle pacing as an alternative to biventricular pacing for cardiac resynchronization therapy: a multicenter experience","volume":"15","author":"Sharma","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.arcmed.2018.12.011_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/130724","article-title":"Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life?","volume":"2013","author":"Li","year":"2013","journal-title":"Cardiol Res Pract"},{"key":"10.1016\/j.arcmed.2018.12.011_bib48","first-page":"123","article-title":"Interatrial shunt devices for heart failure with normal ejection fraction: a technology update","volume":"10","author":"Cuthbert","year":"2017","journal-title":"Med Devices (Auckl)"},{"key":"10.1016\/j.arcmed.2018.12.011_bib49","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.4244\/EIJY14M05_07","article-title":"Left atrial decompression through unidirectional left-to right interatrial shunt for the treatment of left heart failure: first-in-man experience with the V-Wave device","volume":"10","author":"Amat-Santos","year":"2015","journal-title":"EuroIntervention"},{"key":"10.1016\/j.arcmed.2018.12.011_bib50","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/ejhf.111","article-title":"Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure","volume":"16","author":"S\u00f8ndergaard","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.arcmed.2018.12.011_bib51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0002-9149(71)90076-2","article-title":"Left ventricular bypass pump for cardiac assistance","volume":"27","author":"DeBakey","year":"1971","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.arcmed.2018.12.011_bib52","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMoa012175","article-title":"Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure","volume":"345","author":"Rose","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2018.12.011_bib53","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.jacc.2015.04.039","article-title":"Left Ventricular Assist Devices: A Rapidly Evolving Alternativo to Trasplant","volume":"65","author":"Mancini","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arcmed.2018.12.011_bib54","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1161\/CIRCHEARTFAILURE.111.962142","article-title":"Effects of Continuous-Flow Versus Pulsatile-Flow Left Ventricular Assist Devices on Myocardial Unloading and Remodeling","volume":"4","author":"Kato","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.arcmed.2018.12.011_bib55","first-page":"573","article-title":"Comparison of continuous-flow and pulsatile-flow left ventricular assist devices: is there an advantage to pulsatility?","volume":"3","author":"Cheng","year":"2014","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.arcmed.2018.12.011_bib56","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.healun.2017.07.005","article-title":"Eighth annual INTERMACS report: Special focus on framing the impact of adverse events","volume":"36","author":"Kirklin","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.arcmed.2018.12.011_bib57","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1056\/NEJMoa1800866","article-title":"Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure","volume":"378","author":"Mehra","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2018.12.011_bib58","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jchf.2018.05.012","article-title":"from the Endurance trial. HVAD: The ENDURANCE Supplemental Trial","volume":"6","author":"Milano","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.arcmed.2018.12.011_bib59","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1161\/CIRCRESAHA.116.304346","article-title":"Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data","volume":"116","author":"Gy\u00f6ngy\u00f6si","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.arcmed.2018.12.011_bib60","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1093\/eurheartj\/ehx248","article-title":"Global position paper on cardiovascular regenerative medicine","volume":"38","author":"Fern\u00e1ndez-Avil\u00e9s","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arcmed.2018.12.011_bib61","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.cell.2016.05.043","article-title":"Stem Cells: A Renaissance in Human Biology Research","volume":"165","author":"Wu","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.arcmed.2018.12.011_bib62","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1146\/annurev-cellbio-101011-155739","article-title":"Cardiac regenerative capacity and mechanisms","volume":"28","author":"Kikuchi","year":"2012","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.arcmed.2018.12.011_bib63","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ydbio.2011.03.021","article-title":"Recapitulation of developmental cardiogenesis governs the morphological and functional regeneration of adult newt hearts following injury","volume":"354","author":"Witman","year":"2011","journal-title":"Dev Biol"},{"key":"10.1016\/j.arcmed.2018.12.011_bib64","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.devcel.2016.01.018","article-title":"Mechanisms of Cardiac Regeneration","volume":"36","author":"Uygur","year":"2016","journal-title":"Dev Cell"},{"key":"10.1016\/j.arcmed.2018.12.011_bib65","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1126\/science.1200708","article-title":"Transient regenerative potential of the neonatal mouse heart","volume":"331","author":"Porrello","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.arcmed.2018.12.011_bib66","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.yjmcc.2014.12.011","article-title":"A systematic analysis of neonatal mouse heart regeneration after apical resection","volume":"79","author":"Bryant","year":"2015","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.arcmed.2018.12.011_bib67","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(09)61201-0","article-title":"Late donor cardiectomy after paediatric heterotopic cardiac transplantation","volume":"374","author":"Tsang","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2018.12.011_bib68","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCRESAHA.115.307017","article-title":"Functional Recovery of a Human Neonatal Heart After Severe Myocardial Infarction","volume":"118","author":"Haubner","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.arcmed.2018.12.011_bib69","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(12)60195-0","article-title":"Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial","volume":"379","author":"Makkar","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2018.12.011_bib70","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1161\/CIRCRESAHA.114.305567","article-title":"Recent developments in cardiovascular stem cells","volume":"115","author":"Madonna","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.arcmed.2018.12.011_bib71","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/emmm.201100175","article-title":"Regeneration of the heart","volume":"3","author":"Steinhauser","year":"2011","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.arcmed.2018.12.011_bib72","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1038\/s41598-018-25115-2","article-title":"Head-to-head comparison of two engineered cardiac grafts for myocardial repair: From scaffold characterization to pre-clinical testing","volume":"8","author":"Perea-Gil","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.arcmed.2018.12.011_bib73","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1161\/CIRCRESAHA.117.311302","article-title":"Meta-Analysis of Cell Therapy Studies in Heart Failure and Acute Myocardial Infarction","volume":"123","author":"Gy\u00f6ngy\u00f6si","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.arcmed.2018.12.011_bib74","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jacc.2011.11.029","article-title":"Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells","volume":"59","author":"Li","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arcmed.2018.12.011_bib75","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41569-018-0013-0","article-title":"Cell therapy trials for heart regeneration - lessons learned and future directions","volume":"15","author":"Menasch\u00e9","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.arcmed.2018.12.011_bib76","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1161\/CIRCRESAHA.116.304386","article-title":"Meta-analysis of cell therapy trials for patients with heart failure","volume":"116","author":"Fisher","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.arcmed.2018.12.011_bib77","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.mayocp.2014.02.014","article-title":"Breakthroughs in cell therapy for heart disease: focus on cardiosphere-derived cells","volume":"89","author":"Marban","year":"2014","journal-title":"Mayo Clin Proc"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440918309147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440918309147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:47:16Z","timestamp":1759261636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440918309147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":77,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0188440918309147"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2018.12.011","relation":{},"ISSN":["0188-4409"],"issn-type":[{"type":"print","value":"0188-4409"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative Strategies in Heart Failure: Present and Future","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2018.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 IMSS. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}